Key Financial Figures (Standalone, ₹ in Lakhs)

  • Revenue from Operations: ₹802.49 (FY 2024-25: ₹80.73) - 894% increase
  • Other Income: ₹16.04 (FY 2024-25: ₹105.32)
  • Total Income: ₹818.53 (FY 2024-25: ₹186.05)
  • Total Expenses: ₹790.83 (FY 2024-25: ₹187.46)
  • Profit Before Tax: ₹27.70 (FY 2024-25: Loss of ₹1.41)
  • Current Tax: ₹2.88 (FY 2024-25: ₹0.00)
  • Deferred Tax: -₹0.01 (FY 2024-25: -₹0.36)
  • Profit After Tax: ₹24.82 (FY 2024-25: Loss of ₹1.05)
  • EPS: ₹0.21 (FY 2024-25: -₹0.02)
  • Inventory: ₹99.88 (FY 2024-25: ₹5.75)
  • Trade Receivables: ₹143.00 (FY 2024-25: ₹95.26)
  • Cash & Cash Equivalents: ₹122.36 (FY 2024-25: ₹248.24)
  • Paid-up Share Capital: ₹1,158.29 (FY 2024-25: ₹523.89)

Dates of Action

  • AGM Date: September 26, 2026 at 12:30 PM IST through VC/OAVM
  • Book Closure: September 18, 2026 to September 26, 2026
  • E-Voting Period: September 23, 2026 (9:00 AM) to September 25, 2026 (5:00 PM)
  • Cut-off Date for E-Voting: September 18, 2026
  • Board Report Date: August 31, 2026
  • Auditor's Report Date: May 14, 2026

Parties Involved

  • Stock Exchange: BSE Limited
  • Statutory Auditors: M/S PPKG & CO, Chartered Accountants
  • Secretarial Auditors: Kashinath Sahu & Co
  • RTA: M/s. CIL Securities Limited
  • Bankers: ICICI Bank Limited
  • Scrutinizer: PCS Kashinath Sahu

Capital Structure Impact

  • Authorized Share Capital remained unchanged at ₹22.00 crore
  • Paid-up Share Capital increased from ₹5.24 crore to ₹11.58 crore due to conversion of 63,44,000 Convertible Equity Share Warrants
  • 36,81,000 warrants were outstanding as of March 31, 2026, of which 29,00,999 were subsequently converted and 7,80,001 were forfeited
  • Warrants were issued at ₹20 per warrant (₹10 face value + ₹10 premium)

Board and Governance Matters

Current Board Composition (as of March 31, 2026):

1. Mr. Venkata Rao Sadhanala - Managing Director (DIN: 02906370)

2. Mr. Dasi Reddy Rakesh - Non-Executive, Non-Independent Director (DIN: 07112785)

3. Mr. Swapneswar Mishra - Non-Executive, Non-Independent Director (DIN: 09594775)

4. Mr. Gundluru Reddeppa - Non-Executive, Independent Director (DIN: 10419527)

5. Mrs. Padmaja Kalyani Sadhanala - Non-Executive, Non-Independent Director (DIN: 03096445)

6. Mr. Revoor Ramachandra - Non-Executive, Independent Director (DIN: 00490051)

AGM Agenda Items:

1. Adoption of audited financial statements

2. Re-appointment of Mr. Swapneswar Mishra who retires by rotation

3. Special resolution to change designation of Mr. Venkata Rao Sadhanala from Whole Time Director to Managing Director with remuneration of ₹30 lakh per annum for 5 years (March 11, 2026 to March 10, 2031)

4. Regularization of Mrs. Padmaja Kalyani Sadhanala as Non-Executive Non-Independent Director

5. Regularization of Mr. Revoor Ramachandra as Non-Executive Independent Director for a 5-year term (March 30, 2026 to March 29, 2031)

Scheme of Amalgamation

  • Board approved scheme on November 12, 2025 for amalgamation of Hatri Pharma Private Limited (Transferor Company) with Venmax Drugs (Transferee Company)
  • Received No Objection Certificate from BSE on May 15, 2026
  • Filed First Motion Application with NCLT Hyderabad on August 1, 2026
  • Scheme pending regulatory approvals, no financial impact reflected in current statements

Related Party Transactions

  • Unsecured loans to related parties: ₹565.40 lakhs
  • Includes loans to Blue Nile Capital Advisory Limited (₹562.55 lakhs), Omega AG Seeds Punjab Limited (₹2.85 lakhs)
  • Loan from Mr. Venkata Rao Sadhanala: ₹7.00 lakhs
  • Loan from Somani Herbs and Agro Products India Private Limited: ₹2.96 lakhs

Dividend and Reserves

  • No dividend recommended for FY 2025-26
  • ₹24.82 lakhs transferred to General Reserve

Financial Impact Disclosure

All material financial impacts have been quantified in the disclosure. The proposed amalgamation with Hatri Pharma Private Limited may have future financial impact subject to regulatory approvals.